Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis

被引：3

作者：

Sun, Margaret Man-Ger ^{[1
,2
,3
]}

Pope, Janet E. ^{[1
,2
,3
,4
]}

机构：

[1] Schulich Sch Med & Dent, London, ON, Canada

[2] Western Univ, London, ON, Canada

[3] St Josephs Hlth Care, Dept Med, Div Rheumatol, London, ON, Canada

[4] St Josephs Hlth Care, Div Rheumatol, 268 Grosvenor St, London, ON N6A 4V2, Canada

来源：

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2022年 / 36卷 / 04期

关键词：

Giant cell arteritis; Polymyalgia rheumatica; Treatment; Biologics; Glucocorticoids; Tocilizumab; Emerging therapies; PLACEBO-CONTROLLED TRIAL; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; DOUBLE-BLIND; CLASSIFICATION CRITERIA; RHEUMATISM/AMERICAN COLLEGE; DISEASE-ACTIVITY; EUROPEAN LEAGUE; ISCHEMIC COMPLICATIONS; PROMOTER POLYMORPHISM; 2015; RECOMMENDATIONS;

D O I：

10.1016/j.berh.2023.101822

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

For decades, aside from prednisone and the occasional use of im-mune suppressive drugs such as methotrexate, there was little to offer patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). However, there is a great interest in various steroid sparing treatments in both these conditions. This paper aims to provide an overview of our current knowledge of PMR and GCA, examining their similarities and distinctions in terms of clinical presentation, diagnosis, and treatment, with emphasis placed on reviewing recent and ongoing research efforts on emerging treatment. Multiple recent and ongoing clinical trials are demon-strating new therapeutics that will provide benefit and contribute to the evolution of clinical guidelines and standard of care for patients with GCA and/or PMR.& COPY; 2023 Elsevier Ltd. All rights reserved.

引用

页数：12

共 102 条

[1] Increased Mortality for Individuals With Giant Cell Arteritis: A Population-Based Study [J].

Barra, Lillian ;

Pope, Janet E. ;

Pequeno, Priscila ;

Gatley, Jodi M. ;

Widdifield, Jessica .

ARTHRITIS CARE & RESEARCH, 2022, 74 (08) :1294-1299

[2] Incidence and prevalence of giant cell arteritis in Ontario, Canada [J].

Barra, Lillian ;

Pope, Janet E. ;

Pequeno, Priscila ;

Saxena, Farah E. ;

Bell, Mary ;

Haaland, Derek ;

Widdifield, Jessica .

RHEUMATOLOGY, 2020, 59 (11) :3250-3258

[3]

Bas-Lando M, 2007, CLIN EXP RHEUMATOL, V25, pS15

[4]

Bergner R, 2021, Arthritis Rheumatol, V73

[5]

Boiardi L, 2006, J RHEUMATOL, V33, P703

[6] RESULTS OF ONE YEAR OBSERVATIONAL EXTENSION OF THE BRIDGE-PMR STUDY, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL WITH RITUXIMAB IN POLYMYALGIA RHEUMATICA. [J].

Bolhuis, T. ;

Marsman, D. ;

Den Broeder, A. ;

Den Broeder, N. ;

Van der Maas, A. .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 :377-378

[7] Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial [J].

Bonelli, Michael ;

Radner, Helga ;

Kerschbaumer, Andreas ;

Mrak, Daniel ;

Durechova, Martina ;

Stieger, Jutta ;

Husic, Rusmir ;

Mandl, Peter ;

Smolen, Josef S. ;

Dejaco, Christian ;

Aletaha, Daniel .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) :838-844

[8]

Brack A, 1999, ARTHRITIS RHEUM, V42, P311, DOI 10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO

[9]

2-F

[10] Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis [J].

Brennan, David N. ;

Ungprasert, Patompong ;

Warrington, Kenneth J. ;

Koster, Matthew J. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) :529-537

← 1 2 3 4 5 6 7 8 9 10 →